Skip to main content
SpringerLink
Log in

Orbital inflammatory disease secondary to a single-dose administration of zoledronic acid for treatment of postmenopausal osteoporosis

  • Case Report
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

A 60-year-old woman received a single 5-mg dose of zoledronic acid (Aclasta®) for treatment of postmenopausal osteoporosis. One day after receiving the drug, she acutely developed a painful periorbital swelling, chemosis, and hyperemia in the right eye. The condition worsened despite initial treatment with topical steroids. An orbital CT scan showed right eye proptosis, eyelid edema, and intraorbital fat stranding. A diagnosis of orbital inflammatory disease was made, and the patient was treated with high-dose oral steroids (prednisone 80 mg/day) tapered along 6 weeks. The symptoms and the swelling reduced progressively after initiating oral prednisone, and after 12 days, there was complete resolution of the condition. The patient remained symptom free and had no remission after the treatment interruption.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Fraunfelder FW, Fraunfelder FT (2003) Bisphosphonates and ocular inflammation. N Engl J Med 348(12):1187–1188

    Article  PubMed  Google Scholar 

  2. Geusens PP, Lems WF (2007) Fracture prevention in postmenopausal women with osteoporosis by an annual infusion of zoledronic acid. Ned Tijdschr Geneeskd 151(26):1445–1448

    CAS  PubMed  Google Scholar 

  3. Kilickap S et al (2008) A case report: zoledronic acid-induced anterior uveitis. Med Oncol 25(2):238–240

    Article  PubMed  Google Scholar 

  4. Woo TC, Joseph DJ, Wilkinson R (2006) Serious ocular complications of zoledronate. Clin Oncol (R Coll Radiol) 18(7):545–546

    CAS  Google Scholar 

  5. Ryan PJ, Sampath R (2001) Idiopathic orbital inflammation following intravenous pamidronate. Rheumatology (Oxford) 40(8):956–957

    Article  CAS  Google Scholar 

  6. Subramanian PS et al (2003) Orbital inflammatory disease after pamidronate treatment for metastatic prostate cancer. Arch Ophthalmol 121(9):1335–1336

    Article  PubMed  Google Scholar 

  7. Sharma NS et al (2008) Zoledronic acid infusion and orbital inflammatory disease. N Engl J Med 359(13):1410–1411

    Article  CAS  PubMed  Google Scholar 

  8. Phillips PM, Newman SA (2008) Orbital inflammatory disease after intravenous infusion of zoledronate for treatment of metastatic renal cell carcinoma. Arch Ophthalmol 126(1):137–139

    Article  PubMed  Google Scholar 

  9. Gianoukakis AG, Khadavi N, Smith TJ (2008) Cytokines, Graves’ disease, and thyroid-associated ophthalmopathy. Thyroid 18(9):953–958

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology and Otolaringology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

    F. Procianoy & E. Procianoy

Authors
  1. F. Procianoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Procianoy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. Procianoy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Procianoy, F., Procianoy, E. Orbital inflammatory disease secondary to a single-dose administration of zoledronic acid for treatment of postmenopausal osteoporosis. Osteoporos Int 21, 1057–1058 (2010). https://doi.org/10.1007/s00198-009-1048-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-009-1048-1

Keywords

Search

Navigation